CN116500014A - Method for simultaneously and quantitatively detecting concentration of uric acid and creatinine in complex matrix based on paper chromatography and surface-enhanced Raman scattering technology - Google Patents
Method for simultaneously and quantitatively detecting concentration of uric acid and creatinine in complex matrix based on paper chromatography and surface-enhanced Raman scattering technology Download PDFInfo
- Publication number
- CN116500014A CN116500014A CN202310508916.7A CN202310508916A CN116500014A CN 116500014 A CN116500014 A CN 116500014A CN 202310508916 A CN202310508916 A CN 202310508916A CN 116500014 A CN116500014 A CN 116500014A
- Authority
- CN
- China
- Prior art keywords
- uric acid
- creatinine
- raman scattering
- enhanced raman
- sers
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 title claims abstract description 176
- 238000004416 surface enhanced Raman spectroscopy Methods 0.000 title claims abstract description 109
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 title claims abstract description 92
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 title claims abstract description 92
- 229940116269 uric acid Drugs 0.000 title claims abstract description 92
- 229940109239 creatinine Drugs 0.000 title claims abstract description 88
- 238000000034 method Methods 0.000 title claims abstract description 35
- 239000011159 matrix material Substances 0.000 title claims abstract description 29
- 238000004816 paper chromatography Methods 0.000 title claims abstract description 25
- 238000005516 engineering process Methods 0.000 title claims abstract description 24
- 239000000758 substrate Substances 0.000 claims abstract description 74
- 238000001514 detection method Methods 0.000 claims abstract description 56
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 34
- 210000002700 urine Anatomy 0.000 claims abstract description 15
- 239000000243 solution Substances 0.000 claims description 43
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 239000000463 material Substances 0.000 claims description 19
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 16
- 238000007605 air drying Methods 0.000 claims description 14
- 239000008367 deionised water Substances 0.000 claims description 12
- 229910021641 deionized water Inorganic materials 0.000 claims description 12
- 239000002105 nanoparticle Substances 0.000 claims description 12
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims description 11
- 238000000926 separation method Methods 0.000 claims description 11
- 229910052709 silver Inorganic materials 0.000 claims description 11
- 239000004332 silver Substances 0.000 claims description 11
- 239000011259 mixed solution Substances 0.000 claims description 10
- 238000004587 chromatography analysis Methods 0.000 claims description 9
- 238000001228 spectrum Methods 0.000 claims description 8
- 238000005406 washing Methods 0.000 claims description 8
- FOIXSVOLVBLSDH-UHFFFAOYSA-N Silver ion Chemical compound [Ag+] FOIXSVOLVBLSDH-UHFFFAOYSA-N 0.000 claims description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 claims description 6
- 239000011521 glass Substances 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 230000001629 suppression Effects 0.000 claims description 5
- 238000013375 chromatographic separation Methods 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- 239000002244 precipitate Substances 0.000 claims description 4
- 238000004445 quantitative analysis Methods 0.000 claims description 4
- 239000001509 sodium citrate Substances 0.000 claims description 4
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 4
- 238000009835 boiling Methods 0.000 claims description 3
- 239000001913 cellulose Substances 0.000 claims description 3
- 229920002678 cellulose Polymers 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- 210000002966 serum Anatomy 0.000 claims description 3
- 229910001961 silver nitrate Inorganic materials 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 2
- 210000001138 tear Anatomy 0.000 claims description 2
- 239000012141 concentrate Substances 0.000 claims 3
- 238000001069 Raman spectroscopy Methods 0.000 abstract description 5
- 230000002860 competitive effect Effects 0.000 abstract description 5
- 238000001179 sorption measurement Methods 0.000 abstract description 5
- 239000013076 target substance Substances 0.000 abstract description 3
- 238000011065 in-situ storage Methods 0.000 abstract description 2
- 150000008064 anhydrides Chemical class 0.000 abstract 1
- 210000003205 muscle Anatomy 0.000 abstract 1
- 239000000126 substance Substances 0.000 description 13
- 230000000694 effects Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- VYXSBFYARXAAKO-WTKGSRSZSA-N chembl402140 Chemical compound Cl.C1=2C=C(C)C(NCC)=CC=2OC2=C\C(=N/CC)C(C)=CC2=C1C1=CC=CC=C1C(=O)OCC VYXSBFYARXAAKO-WTKGSRSZSA-N 0.000 description 4
- 238000005070 sampling Methods 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 239000012086 standard solution Substances 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 208000017169 kidney disease Diseases 0.000 description 3
- 239000012452 mother liquor Substances 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000001000 micrograph Methods 0.000 description 2
- 230000004144 purine metabolism Effects 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 201000001431 Hyperuricemia Diseases 0.000 description 1
- 238000007375 Jaffe assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000000622 liquid--liquid extraction Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- IYDGMDWEHDFVQI-UHFFFAOYSA-N phosphoric acid;trioxotungsten Chemical compound O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.OP(O)(O)=O IYDGMDWEHDFVQI-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/65—Raman scattering
- G01N21/658—Raman scattering enhancement Raman, e.g. surface plasmons
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/90—Plate chromatography, e.g. thin layer or paper chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/90—Plate chromatography, e.g. thin layer or paper chromatography
- G01N30/94—Development
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
Abstract
A method for simultaneously and quantitatively detecting uric acid and creatinine concentration in a complex matrix based on paper chromatography and surface enhanced Raman scattering technology relates to the field of detection methods. The invention aims to solve the problems that the existing creatinine and uric acid detection method is easy to be interfered, needs a large-scale instrument, is complex in operation and difficult to detect on site, and simple surface enhanced Raman scattering is limited by competitive adsorption and is difficult to accurately detect target substances in a complex matrix. 1. Preparing a paper chromatograph-surface enhanced Raman scattering substrate based on an aggregation-promoting agent induced assembly technology; 2. separating and enriching uric acid and creatinine in a complex solution at positions with specific shift values of 0 and 0.64 by using a paper chromatography-surface enhanced Raman scattering substrate; 3. in-situ detection of uric acid and muscle using portable raman spectrometerThe surface enhanced raman scattering signal of the anhydride was analyzed quantitatively. The detection limit of the invention on uric acid and creatinine in urine is respectively as low as 10 ‑5 M and 10 ‑4 M, satisfy actual detection demand.
Description
Technical Field
The invention relates to the field of detection methods, in particular to a method for simultaneously and quantitatively detecting uric acid and creatinine concentration in a complex matrix based on paper chromatography and a surface enhanced Raman scattering technology.
Background
Uric acid is a final product of purine metabolism in vivo, is slightly soluble in water, is usually produced by kidney metabolism, is almost completely discharged outside a human body through urine, has a normal value of 0.15-0.4 mM of serum uric acid of healthy adult human, has a normal value of 1.1-4.4 mM in urine, causes abnormal uric acid metabolism due to purine metabolic disorder and kidney diseases, is an optimal index for diagnosing hyperuricemia caused by abnormal purine metabolism, and can be used for diagnosing and monitoring kidney diseases, so that uric acid detection has important significance.
Creatinine is a metabolic product of creatine in vivo, and is discharged from the body after being filtered by glomeruli, the normal value of urine creatinine of women is 7.9-14.1 mmol/24h, and the normal value of creatinine of men is 9.7-24.7 mmol/24h. Urinary creatinine and blood creatinine are important indexes for detecting kidney diseases and evaluating the development of the diseases, are closely related to the health condition of the kidney, and are often used as internal standard substances for correcting the content of other substances in urine, such as medicines and toxins, so that the development of a method for rapidly detecting creatinine has important significance.
At present, the method for detecting uric acid mainly comprises a phosphotungstic acid colorimetric method and an enzymatic method, but the operation is complex, and the detection cost is high. Common methods of urinary creatinine are the Jaffe reaction method and the enzyme method, but due to interference of other substances in body fluid, the detection specificity is low, and other detection methods such as HPLC and chromatography-mass spectrometry have extremely low detection limit, but equipment is expensive and cannot be detected on site.
The Surface Enhanced Raman Scattering (SERS) technology is a fast and high-sensitivity detection technology, and can provide molecular fingerprint information of a detected object, so that the SERS technology has been widely studied in recent years, but is limited by competitive adsorption effect, the SERS technology is difficult to complete detection tasks in a complex matrix, and a detected substance signal with a small raman cross section can be completely submerged and cannot be accurately detected. Paper Chromatography (PC) is an effective liquid-liquid partition chromatography, and as the partition coefficients of the constituent substances in the sample in the stationary phase and the mobile phase are different, the moving speeds of the constituent substances on the filter paper are different, and finally, the respective substances stay at different positions on the filter paper to realize separation. The specific shift value (Rf) is often used to represent the distribution of each substance after separation. And assembling nano particles on the surface of the chromatographic paper to prepare a PC-SERS substrate, and combining two technologies to quickly realize simultaneous separation and detection of uric acid and creatinine in a complex matrix. However, simple SERS detection has high sensitivity, but detection of a target substance in a complex medium is difficult to achieve due to competitive adsorption.
Disclosure of Invention
The invention aims to solve the problems that the existing creatinine and uric acid detection method is easy to be interfered, a large-scale instrument is needed, the operation is complicated, the field detection is difficult, the simple surface enhanced Raman scattering is limited by competitive adsorption, and the target substance is difficult to accurately detect in a complex matrix, and provides a method for simultaneously and quantitatively detecting the concentration of uric acid and creatinine in the complex matrix based on paper chromatography and the surface enhanced Raman scattering technology.
The invention designs a PC-SERS substrate, effectively overcomes interference caused by competitive adsorption to SERS detection, and provides a method which does not need pretreatment, has low cost and high sensitivity and can be used for detecting uric acid and creatinine in complex matrixes simultaneously by matching with a portable Raman spectrometer.
The method for simultaneously and quantitatively detecting the concentration of uric acid and creatinine in a complex matrix based on paper chromatography and surface-enhanced Raman scattering technology is specifically completed by the following steps:
1. preparing a PC-SERS substrate:
(1) immersing the substrate material into the aggregation-promoting agent solution for a period of time, taking out and air-drying to obtain the substrate material treated by the aggregation-promoting agent;
(2) immersing a base material treated by an aggregation-promoting agent into silver nanoparticle concentrated solution for a period of time, taking out, washing with deionized water, and finally air-drying to obtain a PC-SERS substrate;
2. separation of uric acid and creatinine in complex matrices:
spotting a trace amount of solution to be detected at a position 15mm away from the lower end of the PC-SERS substrate, immersing the lower end of the substrate into a developing agent in a closed container for developing upwards after air drying, taking out the substrate when developing to a chromatography end point, and naturally air drying to obtain the PC-SERS substrate after paper chromatography separation;
3. SERS detects uric acid and creatinine:
and sticking the PC-SERS substrate subjected to paper chromatographic separation on a glass slide for SERS detection, respectively detecting the strongest signals of uric acid and creatinine at the positions with the specific shift value of 0 and 0.64, and quantitatively analyzing according to the characteristic peak intensity after noise suppression and baseline deduction of the spectrum.
The invention is based on wavelet threshold noise reduction, iterative punishment partial least square method, multi-element scattering correction and other algorithms to carry out noise suppression, baseline subtraction and other treatments on the spectrum, and then 1135cm of uric acid is measured -1 1426cm characteristic Peak Strength and creatinine -1 Substituting the characteristic peak intensity into a concentration-characteristic peak intensity curve to obtain the concentration of uric acid and creatinine in the measured solution.
The invention has the beneficial effects that:
1. the PC-SERS substrate prepared by the invention reduces the detection cost while realizing high stability, high accuracy and high sensitivity, can be matched with a portable Raman spectrometer, can be used for large-scale screening of related diseases in a medical laggard area, and provides a new solution for on-site rapid detection of uric acid and creatinine;
2. the invention is based on PC-SERS technology, overcomes the problem of difficult detection of SERS technology in complex matrix to a certain extent, realizes simultaneous detection of uric acid and creatinine, and can directly detect detected substances in complex matrix without pretreatment of samples;
3. according to the detection method, under the detection of creatinine in artificial urine, the PC-SERS substrate prepared by the inventionLimited to 10 -4 M, the lower limit of detection of uric acid can reach 10 -5 M；
4. The invention has the advantages of high detection speed, no pretreatment of samples, low cost, high sensitivity, simultaneous detection of multiple targets and convenient carrying, can overcome the defect that the SERS technology is difficult to complete detection in complex matrixes, and provides a new solution for on-site rapid detection of creatinine and uric acid.
Drawings
FIG. 1 is a schematic diagram of a PC-SERS substrate preparation and in-situ detection method for simultaneous quantitative detection of uric acid and creatinine in a complex matrix according to the present invention;
FIG. 2 is a scanning electron microscope image of a PC-SERS substrate prepared in example 1;
FIG. 3 shows the detection effect of rhodamine 6G on a PC-SERS substrate prepared by using example 1;
FIG. 4 is a normalized comparison chart of SERS signals of a mixed solution to be detected (comprising 1mg/mL of fetal bovine serum, 4mM of glucose, 0.5mM of creatinine and 0.5mM of uric acid) and SERS signals of a uric acid standard solution, wherein the creatinine is creatinine, the mix is the mixed solution to be detected, and the uric acid is uric acid;
FIG. 5 is a waterfall plot of SERS signal plotted at 5mm sampling intervals versus sampling position on a PC-SERS substrate;
FIG. 6 shows the values of the specific shift in the horizontal axis, respectively 1135cm of uric acid -1 1426cm characteristic Peak Strength and creatinine -1 B spline fitting is carried out on the characteristic peak intensity as a longitudinal axis, so that a distribution diagram of a substance to be detected on the PC-SERS substrate is obtained;
FIG. 7 shows uric acid concentration measured with 1135cm uric acid using a PC-SERS substrate -1 Uric acid concentration-characteristic peak intensity curve, R, obtained by adopting B spline fitting method for characteristic peak intensity 2 0.9945;
FIG. 8 shows the concentration of creatinine versus 1426cm of creatinine detected using a PC-SERS substrate -1 Creatinine concentration-characteristic peak intensity curve, R, obtained by adopting B spline fitting method for characteristic peak intensity 2 0.9940;
FIG. 9 is a graph showing the results of quantitative analysis of uric acid concentration in a sample of a test set;
FIG. 10 is a graph showing the results of the quantitative analysis of creatinine concentration in test set samples.
Detailed Description
The first embodiment is as follows: the method for simultaneously and quantitatively detecting uric acid and creatinine concentration in a complex matrix based on paper chromatography and surface-enhanced Raman scattering technology in the embodiment is specifically completed by the following steps:
1. preparing a PC-SERS substrate:
(1) immersing the substrate material into the aggregation-promoting agent solution for a period of time, taking out and air-drying to obtain the substrate material treated by the aggregation-promoting agent;
(2) immersing a base material treated by an aggregation-promoting agent into silver nanoparticle concentrated solution for a period of time, taking out, washing with deionized water, and finally air-drying to obtain a PC-SERS substrate;
2. separation of uric acid and creatinine in complex matrices:
spotting a trace amount of solution to be detected at a position 15mm away from the lower end of the PC-SERS substrate, immersing the lower end of the substrate into a developing agent in a closed container for developing upwards after air drying, taking out the substrate when developing to a chromatography end point, and naturally air drying to obtain the PC-SERS substrate after paper chromatography separation;
3. SERS detects uric acid and creatinine:
and sticking the PC-SERS substrate subjected to paper chromatographic separation on a glass slide for SERS detection, respectively detecting the strongest signals of uric acid and creatinine at the positions with the specific shift value of 0 and 0.64, and quantitatively analyzing according to the characteristic peak intensity after noise suppression and baseline deduction of the spectrum.
The second embodiment is as follows: the present embodiment differs from the specific embodiment in that: the substrate material in the step one (1) is cellulose chromatographic paper; the aggregation-promoting agent solution in the step one (1) is NaCl solution or KCl solution, and the concentration is 10 mmol/L-100 mmol/L. The other steps are the same as in the first embodiment.
And a third specific embodiment: this embodiment differs from the first or second embodiment in that: step one, immersing the substrate material into the aggregation-promoting agent solution for 10 to 60 minutes. The other steps are the same as those of the first or second embodiment.
The specific embodiment IV is as follows: one difference between this embodiment and the first to third embodiments is that: the particle size of silver nano particles in the silver nano particle concentrated solution in the step one (2) is 30 nm-120 nm. The other steps are the same as those of the first to third embodiments.
Fifth embodiment: one to four differences between the present embodiment and the specific embodiment are: the preparation method of the silver nanoparticle concentrated solution in the step one (2) comprises the following steps: dissolving 0.036g of silver nitrate into 200mL of deionized water, stirring and heating to boil the solution, adding 2 mL-8 mL of sodium citrate solution with mass fraction of 1%, keeping boiling for 0.5 h-1 h, stopping heating, cooling to room temperature, centrifuging for 1-3 times, taking precipitate, redissolving in deionized water, and fixing the volume to 1/10-1/4 of the volume before centrifuging. Other steps are the same as those of the first to fourth embodiments.
Specific embodiment six: the present embodiment differs from the first to fifth embodiments in that: immersing the substrate material treated by the aggregation-promoting agent into the silver nanoparticle concentrated solution for 2-24 hours; and (3) in the step (2), deionized water is used for washing for 2 to 5 times, and the washing time is 3 to 6 seconds each time. Other steps are the same as those of the first to fifth embodiments.
Seventh embodiment: one difference between the present embodiment and the first to sixth embodiments is that: the sample application amount of the trace solution to be measured in the second step is 1 mu L-10 mu L; the developing agent in the second step is a mixed solution of water and isopropanol, wherein the volume ratio of the water to the isopropanol is 3:2. Other steps are the same as those of embodiments one to six.
Eighth embodiment: one difference between the present embodiment and the first to seventh embodiments is that: in the second step, the lower end of the PC-SERS substrate is immersed into the developing agent for 3 mm-7 mm, and the developing distance is 30 mm-140 mm when reaching the chromatography end point. The other steps are the same as those of embodiments one to seven.
Detailed description nine: one of the differences between this embodiment and the first to eighth embodiments is: the solution to be detected in the second step is urine, serum or tears. Other steps are the same as those of embodiments one to eight.
Detailed description ten: the present embodiment differs from the first to ninth embodiments in that: the SERS detection range in the third step is 500cm -1 ～1800cm -1 1135cm based on uric acid after acquisition of SERS signal -1 1426cm of characteristic peak intensity and creatinine -1 Quantitative analysis of the intensity of the characteristic peak; and step three, determining the distribution condition of uric acid and creatinine according to the intensity change of the characteristic peak by adopting a laser line scanning mode, and determining the detection position. The other steps are the same as those of embodiments one to nine.
The following examples are used to verify the benefits of the present invention:
example 1: the preparation method of the PC-SERS substrate comprises the following steps:
1. preparing a PC-SERS substrate:
(1) immersing the substrate material into the aggregation-promoting agent solution for 20min, taking out and air-drying to obtain the aggregation-promoting agent treated substrate material;
the substrate material in the step one (1) is cellulose chromatographic paper, and the size is 1cm multiplied by 10cm;
the aggregation-promoting agent solution in the step one (1) is NaCl solution with the concentration of 20mmol/L;
(2) immersing a base material treated by an aggregation-promoting agent into a silver nanoparticle concentrated solution for 4 hours, taking out, washing 3 times by using deionized water for 3s each time to thoroughly remove silver nanoparticles which are not tightly combined with chromatographic paper, and finally air-drying to obtain a PC-SERS substrate;
the particle diameter of silver nano particles in the silver nano particle concentrated solution in the step one (2) is 30 nm-120 nm, and the silver nano particles are prepared by adopting a sodium citrate reduction method, and the specific preparation method comprises the following steps: 0.036g of silver nitrate is dissolved in 200mL of deionized water, stirred and heated until the solution boils, then 5mL of sodium citrate solution with the mass fraction of 1% is added, heating is stopped after the solution is kept boiling for 0.8h, cooling is carried out to room temperature, centrifugation is carried out for 10min at 8000r/min, supernatant is removed, precipitate is taken and redissolved in deionized water, and the volume is fixed to 1/8 of the volume before centrifugation.
FIG. 2 is a scanning electron microscope image of a PC-SERS substrate prepared in example 1;
as can be seen from fig. 2, silver nanoparticles were successfully assembled on the substrate surface, and the particle size and density were relatively uniform.
The PC-SERS substrate prepared in the embodiment 1 is used for detecting rhodamine 6G solutions with different concentrations, and the detection effect is shown in the figure 3;
FIG. 3 shows the detection effect of rhodamine 6G on a PC-SERS substrate prepared by using example 1;
as can be seen from fig. 3: the PC-SERS substrate prepared in example 1 has a detection limit of 100pM to rhodamine 6G, and the prepared substrate has excellent SERS performance.
Example 2: the method for simultaneously and quantitatively detecting uric acid and creatinine concentrations in a complex matrix by using the PC-SERS substrate prepared in the embodiment 1 based on paper chromatography and surface-enhanced Raman scattering technology is specifically completed by the following steps:
1. separation of uric acid and creatinine in complex matrices:
spotting 3 mu L of a trace mixed solution to be tested at a position 15mm away from the lower end of the PC-SERS substrate, airing, immersing the lower end of the substrate into a developing agent in a closed container for developing upwards, taking out the substrate after developing to a chromatography end point, and naturally airing to obtain the PC-SERS substrate after paper chromatography separation;
the concentration of fetal bovine serum in the trace mixed solution to be detected in the first step is 1mg/mL, the concentration of glucose is 4mM, the concentration of creatinine is 0.5mM, and the concentration of uric acid is 0.5mM;
the developing agent in the first step is a mixed solution of water and isopropanol, wherein the volume ratio of the water to the isopropanol is 3:2;
step one, immersing the lower end of the PC-SERS substrate into a developing agent for 5mm, wherein the developing distance is 70mm when the lower end reaches a chromatography end point;
2. SERS detects uric acid and creatinine:
sticking the PC-SERS substrate after paper chromatographic separation on a glass slide for SERS detection, using 785nm laser as an excitation light source, and integrating for 15s, wherein the detection range is 500-1800 cm for 2 times on average -1 Collect every 2.5mmA primary SERS signal, as shown in fig. 5, is a waterfall diagram of SERS signal and sampling position drawn with 5mm as sampling interval; from FIG. 5, it can be seen that uric acid molecules have the strongest signal at Rf value of 0 (0 mm) due to extremely low solubility of uric acid in the developing agent. The strongest creatinine signal was found at Rf value 0.64 (45 mm), indicating that creatinine moved there with the developer. Since isopropanol is volatile, it does not interfere with the measurement. The ratio shift value is taken as the horizontal axis, and 1135cm of uric acid is respectively taken as the horizontal axis -1 1426cm characteristic Peak Strength and creatinine -1 And performing B spline fitting on the characteristic peak intensity as a vertical axis to obtain the distribution of the substances on the PC-SERS substrate as shown in figure 6. The above results demonstrate that uric acid and creatinine cannot be detected simultaneously in a complex matrix based solely on SERS technology, but the PC-SERS substrate described in the present invention enables simultaneous detection of uric acid and creatinine in a complex matrix.
Detecting SERS signals of creatinine standard solution (creatinine 0.5 mM) and uric acid standard solution (uric acid 0.5 mM), detecting SERS signals of mixed solution to be detected (concentration of fetal calf serum in the mixed solution to be detected is 1mg/mL, concentration of glucose is 4mM, concentration of creatinine is 0.5mM, concentration of uric acid is 0.5mM; the obtained SERS signals are normalized and then are plotted in FIG. 4;
as can be seen from fig. 4: the signal of the mixed solution to be detected is almost identical with that of the uric acid standard solution, and several main characteristic peaks of creatinine are almost invisible, because the Raman section of uric acid is far higher than that of creatinine and other interfering substances, signal enhancement hot spots can be preempted by uric acid, and uric acid and creatinine can not be detected in a complex matrix at the same time directly based on SERS technology.
Example 3: the method for simultaneously and quantitatively detecting uric acid and creatinine concentrations in a complex matrix by using the PC-SERS substrate prepared in the embodiment 1 based on paper chromatography and surface-enhanced Raman scattering technology is specifically completed by the following steps:
1. preparing artificial urine with different concentrations of creatinine and uric acid:
accurately weighing pure substance powder of uric acid and creatinine, preparing mother liquor by taking artificial urine as a solvent, dripping 100mM NaOH solution into the uric acid mother liquor until the uric acid precipitate is completely dissolved, carrying out ultrasonic treatment for 5min to uniformly disperse the solution, extracting a proper amount of the two mother liquors by using a pipette gun, mixing, and diluting the mixed mother liquor by the artificial urine to obtain the artificial urine with different concentrations of creatinine and uric acid (the concentration of the uric acid in the artificial urine is 1 mu M-4 mM, and the concentration of the creatinine is 1 mu M-30 mM);
2. 3uL of artificial urine with uric acid and creatinine with different concentrations is spotted on a PC-SERS substrate 15mm away from the bottom to be air-dried, a closed container is filled with a developing agent prepared by water and isopropanol=3:2, and the container is shaken to accelerate the speed of the developing agent vapor reaching a saturated state in the container;
3. suspending the PC-SERS substrate in a container, immersing the bottom of the substrate in a developing agent for 5mm, developing upwards, taking out when the developing distance is 70mm, and airing in a fume hood;
4. sticking the separated and air-dried PC-SERS substrate on a glass slide for SERS detection, using 785nm laser as an excitation light source, and integrating for 15s, wherein the detection range is 500-1800 cm for 2 times on average -1 SERS signals of uric acid and creatinine are detected at positions with the specific shift value of 0 and 0.64 respectively, and 20 spectrums are collected for each gradient concentration to obtain average spectrums for subsequent curve fitting.
Based on wavelet threshold noise reduction, iterative punishment partial least square method, multi-element scattering correction and other algorithms are used for carrying out noise suppression, baseline subtraction and other treatments on the spectrum, and then 1135cm of uric acid is measured -1 1426cm characteristic Peak Strength and creatinine -1 The characteristic peak intensity is averaged, and the concentration-characteristic peak intensity curves of uric acid and creatinine are obtained by using a B-spline fitting method, as shown in FIG. 7 and FIG. 8, respectively, and R of the fitting curve is calculated 2 0.9945 and 0.9940, respectively.
The method is used for detecting artificial urine mixed with uric acid and creatinine with different concentrations, uric acid detected at the positions of Rf=0 and Rf=0.64 is substituted into a fitting curve to obtain the concentration of uric acid and creatinine in the solution, so that simultaneous quantitative detection of uric acid and creatinine is realized, and a test set of uric acid and creatinine respectively comprises 30 spectra. Fig. 9 and fig. 10 show the test results of uric acid and creatinine in the test set sample, respectively, and it can be seen that the predicted value and the actual value show good consistency, and the relative deviation between most of the predicted values and the actual value is less than 10%, which illustrates that the present embodiment can obtain good detection effects on uric acid and creatinine in complex substrates.
Claims (10)
1. A method for simultaneously and quantitatively detecting uric acid and creatinine concentration in a complex matrix based on paper chromatography and surface-enhanced Raman scattering technology is characterized by comprising the following steps:
1. preparing a PC-SERS substrate:
(1) immersing the substrate material into the aggregation-promoting agent solution for a period of time, taking out and air-drying to obtain the substrate material treated by the aggregation-promoting agent;
(2) immersing a base material treated by an aggregation-promoting agent into silver nanoparticle concentrated solution for a period of time, taking out, washing with deionized water, and finally air-drying to obtain a PC-SERS substrate;
2. separation of uric acid and creatinine in complex matrices:
spotting a trace amount of solution to be detected at a position 15mm away from the lower end of the PC-SERS substrate, immersing the lower end of the substrate into a developing agent in a closed container for developing upwards after air drying, taking out the substrate when developing to a chromatography end point, and naturally air drying to obtain the PC-SERS substrate after paper chromatography separation;
3. SERS detects uric acid and creatinine:
and sticking the PC-SERS substrate subjected to paper chromatographic separation on a glass slide for SERS detection, respectively detecting the strongest signals of uric acid and creatinine at the positions with the specific shift value of 0 and 0.64, and quantitatively analyzing according to the characteristic peak intensity after noise suppression and baseline deduction of the spectrum.
2. The method for simultaneous quantitative detection of uric acid and creatinine concentrations in a complex matrix based on paper chromatography and surface enhanced raman scattering techniques as defined in claim 1, wherein the substrate material in step one (1) is cellulose chromatography paper; the aggregation-promoting agent solution in the step one (1) is NaCl solution or KCl solution, and the concentration is 10 mmol/L-100 mmol/L.
3. The method for simultaneous quantitative detection of uric acid and creatinine concentrations in a complex matrix based on paper chromatography and surface enhanced raman scattering techniques as defined in claim 1, wherein the step one (1) is to immerse the substrate material in the aggregation-promoting agent solution for 10min to 60min.
4. The method for simultaneous quantitative detection of uric acid and creatinine concentrations in a complex matrix based on paper chromatography and surface-enhanced raman scattering (surface-enhanced raman scattering) according to claim 1, wherein the particle size of silver nanoparticles in the silver nanoparticle concentrate in step one (2) is 30nm to 120nm.
5. The method for simultaneous quantitative detection of uric acid and creatinine concentrations in a complex matrix based on paper chromatography and surface enhanced raman scattering (surface enhanced raman scattering) according to claim 1, wherein the preparation method of the silver nanoparticle concentrate in step one (2) is as follows: dissolving 0.036g of silver nitrate into 200mL of deionized water, stirring and heating to boil the solution, adding 2 mL-8 mL of sodium citrate solution with mass fraction of 1%, keeping boiling for 0.5 h-1 h, stopping heating, cooling to room temperature, centrifuging for 1-3 times, taking precipitate, redissolving in deionized water, and fixing the volume to 1/10-1/4 of the volume before centrifuging.
6. The method for simultaneous quantitative detection of uric acid and creatinine concentrations in a complex matrix based on paper chromatography and surface-enhanced raman scattering (surface-enhanced raman scattering) technology according to claim 1, wherein in step one (2), the aggregation-promoting agent-treated base material is immersed in a silver nanoparticle concentrate for 2-24 h; and (3) in the step (2), deionized water is used for washing for 2 to 5 times, and the washing time is 3 to 6 seconds each time.
7. The method for simultaneously and quantitatively detecting uric acid and creatinine concentrations in a complex matrix based on paper chromatography and surface-enhanced Raman scattering technology as defined in claim 1, wherein the sample application amount of the trace amount of the solution to be detected in the second step is 1-10 mu L; the developing agent in the second step is a mixed solution of water and isopropanol, wherein the volume ratio of the water to the isopropanol is 3:2.
8. The method for simultaneously and quantitatively detecting uric acid and creatinine concentrations in a complex matrix based on paper chromatography and surface-enhanced Raman scattering technology as claimed in claim 1, wherein the lower end of the PC-SERS substrate is immersed in a developing agent for 3-7 mm, and the developing distance is 30-140 mm when reaching the chromatography end point.
9. The method for simultaneously and quantitatively detecting uric acid and creatinine concentrations in a complex matrix based on paper chromatography and surface-enhanced raman scattering (SERS) according to claim 1, wherein the solution to be detected in the second step is urine, serum or tear.
10. The method for simultaneous quantitative detection of uric acid and creatinine concentrations in a complex matrix based on paper chromatography and Surface Enhanced Raman Scattering (SERS) techniques as defined in claim 1, wherein the SERS detection in step three is performed in a range of 500cm -1 ～1800cm -1 1135cm based on uric acid after acquisition of SERS signal -1 1426cm of characteristic peak intensity and creatinine -1 Quantitative analysis of the intensity of the characteristic peak; and step three, determining the distribution condition of uric acid and creatinine according to the intensity change of the characteristic peak by adopting a laser line scanning mode, and determining the detection position.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310508916.7A CN116500014A (en) | 2023-05-08 | 2023-05-08 | Method for simultaneously and quantitatively detecting concentration of uric acid and creatinine in complex matrix based on paper chromatography and surface-enhanced Raman scattering technology |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310508916.7A CN116500014A (en) | 2023-05-08 | 2023-05-08 | Method for simultaneously and quantitatively detecting concentration of uric acid and creatinine in complex matrix based on paper chromatography and surface-enhanced Raman scattering technology |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116500014A true CN116500014A (en) | 2023-07-28 |
Family
ID=87328181
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310508916.7A Pending CN116500014A (en) | 2023-05-08 | 2023-05-08 | Method for simultaneously and quantitatively detecting concentration of uric acid and creatinine in complex matrix based on paper chromatography and surface-enhanced Raman scattering technology |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116500014A (en) |
-
2023
- 2023-05-08 CN CN202310508916.7A patent/CN116500014A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Li et al. | Chromatographic separation and detection of contaminants from whole milk powder using a chitosan-modified silver nanoparticles surface-enhanced Raman scattering device | |
| CN109001176A (en) | A kind of preparation method of the SERS substrate of Au@Ag nanoparticle and method using substrate detection glucose | |
| Muhammad et al. | Fast probing of glucose and fructose in plant tissues via plasmonic affinity sandwich assay with molecularly-imprinted extraction microprobes | |
| CN108562568B (en) | Method for identifying and detecting quality of rhizoma alismatis medicinal material | |
| CN111269577B (en) | Nano-silver loaded POSS (polyhedral oligomeric silsesquioxane) polymer composite material as well as preparation method and application thereof | |
| CN110618124A (en) | Method for detecting content of tyramine in aquatic product based on azo coupling reaction and surface enhanced resonance Raman scattering | |
| JP2013541009A (en) | Sample detection method | |
| Yan et al. | Gold nanoparticle enriched by Q sepharose spheres for chemical reaction tandem SERS detection of malondialdehyde | |
| Ramezani et al. | Metal-coded hydrogel magnetic molecularly imprinted polymer for preconcentration and cleanup of sarcosine: Determination in urine; coupled to on-column capillary electrophoresis | |
| Cervinkova et al. | A fully validated bioanalytical method using an UHPLC–MS/MS system for quantification of DNA and RNA oxidative stress biomarkers | |
| CN116500014A (en) | Method for simultaneously and quantitatively detecting concentration of uric acid and creatinine in complex matrix based on paper chromatography and surface-enhanced Raman scattering technology | |
| CN112697770A (en) | Method for measuring glutaraldehyde in water based on metal organic framework material composite substrate surface enhanced Raman spectroscopy | |
| CN101246176A (en) | Mass spectrum kit for detecting squamous-cell carcinoma antigen feminine cervical carcinoma serum protein | |
| CN112611814B (en) | Method for determining 1, 5-anhydroglucitol in dried blood slices | |
| CN108982466A (en) | A method of for antibiotic field quick detection in Amoxicillin in water body | |
| CN114324647A (en) | Method for simultaneously measuring vitamin K in milk powder1And K2Method and application of | |
| Guo et al. | A determination method for clenbuterol residue in pork based on optimal particle size gold colloid using SERS | |
| Cui et al. | Hierarchical structure SERS biosensor: A machine learning-driven ultra-sensitive platform for trace detection of amygdalin | |
| CN107643263B (en) | Biomolecule detection method based on optical comb coherent imaging analysis | |
| Schorr et al. | Chemical conjugation to differentiate monosaccharides by Raman and surface enhanced Raman spectroscopy | |
| CN116858978B (en) | Method for simultaneously detecting insulin aspart and insulin deglutition and plasma sample processing method thereof | |
| CN117420245A (en) | Detection method of human dry blood spot ceramide and kit for detecting ceramide | |
| CN114965417A (en) | Method for rapidly detecting methyl mercury by surface enhanced Raman scattering | |
| CN112986426B (en) | Analysis method for in vitro screening enzyme capable of catalyzing and cracking homocysteine | |
| CN117571869A (en) | Screening method of xanthine oxidase inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |